Aktis Oncology (NASDAQ:AKTS) Stock Price Up 12.3% – Still a Buy?

Shares of Aktis Oncology (NASDAQ:AKTS) rose 12.3% during mid-day trading on Thursday . The company traded as high as $23.18 and last traded at $22.90. Approximately 197,425 shares traded hands during mid-day trading, a decline of 46% from the average daily volume of 368,199 shares. The stock had previously closed at $20.40.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Aktis Oncology to a “hold” rating in a report on Saturday, January 17th.

Aktis Oncology Trading Up 9.8%

Insider Activity at Aktis Oncology

In other Aktis Oncology news, Director Helen Susan Kim bought 835,000 shares of the stock in a transaction on Monday, January 12th. The shares were purchased at an average cost of $18.00 per share, with a total value of $15,030,000.00. Following the completion of the transaction, the director directly owned 5,671,825 shares of the company’s stock, valued at $102,092,850. This represents a 17.26% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm bought 1,112,777 shares of the business’s stock in a transaction on Monday, January 12th. The shares were bought at an average price of $18.00 per share, for a total transaction of $20,029,986.00. Following the completion of the acquisition, the insider owned 10,260,064 shares of the company’s stock, valued at approximately $184,681,152. This represents a 12.17% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 6,117,776 shares of company stock worth $110,119,968 over the last quarter. 3.30% of the stock is currently owned by corporate insiders.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.